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ABSTRACT
Many adeno-associated virus (AAV) serotypes efficiently transduce the retina when delivered to the subretinal space but show
limited success when delivered to the vitreous due to the inner limiting membrane (ILM). Subretinal delivery of AAV serotype 2
(AAV2) and its heparan sulfate (HS)-binding-deficient capsid led to similar expression, indicating transduction of the outer ret-
ina occurred by HS-independent mechanisms. However, intravitreal delivery of HS-ablated recombinant AAV2 (rAAV2) led to a
300-fold decrease in transduction compared to AAV2. Fluorescence in situ hybridization of AAV transgenes was used to identify
differences in retinal trafficking and revealed that HS binding was responsible for AAV2 accumulation at the ILM. This mecha-
nism was tested on human ex vivo retinas and showed similar accumulation with HS-binding AAV2 capsid only. To evaluate if
HS binding could be applied to other AAV serotypes to enhance their transduction, AAV1 and AAV8 were modified to bind HS
with a single-amino-acid mutation and tested in mice. Both HS-binding mutants of AAV1 and AAV8 had higher intravitreal
transduction than their non-HS-binding parent capsid due to increased retinal accumulation. To understand the influence that
HS binding has on tropism, chimeric AAV2 capsids with dual-glycan usage were tested intravitreally in mice. Compared to HS
binding alone, these chimeric capsids displayed enhanced transduction that was correlated with a change in tropism. Taken to-
gether, these data indicate that HS binding serves to sequester AAV capsids from the vitreous to the ILM but does not influence
retinal tropism. The enhanced retinal transduction of HS-binding capsids provides a rational design strategy for engineering
capsids for intravitreal delivery.
IMPORTANCE
Adeno-associated virus (AAV) has become the vector of choice for viral gene transfer and has shown great promise in clinical
trials. The need for development of an easy, less invasive injection route for ocular gene therapy is met by intravitreal delivery,
but delivery of AAV by this route results in poor transduction outcomes. The inner limiting membrane (ILM) creates a barrier
separating the vitreous and the retina. Binding of AAV to heparan sulfate proteoglycan (HSPG) at the ILMmay allow the virus to
traverse this barrier for better retinal transduction.We show that HSPG binding is correlated with greater accumulation and
penetration of AAV in the retina. We demonstrated that this accumulation is conserved across mouse and human retinas and
that the addition of HSPG binding to other AAV capsids can increase the number of vectors accumulating at the ILMwithout
dictating tropism.
Adeno-associated virus (AAV) is a small (25-nm), nonpatho-genic virus that has been extensively studied as a vector for
gene transfer applications (1–3). The virus consists of two parts:
the viral genome and the protein capsid. The viral genome can be
largely replaced with a desired transgene to create recombinant
AAV (rAAV) vectors used for gene delivery. The protein capsid is
responsible for cell attachment and entry via a variety of glycans
and cell surface receptors. There are 11 naturally occurring sero-
types of AAV, denoted AAV1 to AAV11. Glycans and receptors
have been elucidated for several AAV serotypes. Heparan sulfate
proteoglycan (HSPG) has been shown to be used for both rAAV2
and rAAV3 cell entry (4). rAAV6 displays dual-glycan interaction
with HSPG and sialic acid; however, HSPG binding alone is insuf-
ficient for cellular entry (5). Various linkages of sialic acid are
important for the transduction of the rAAV1, rAAV4, and rAAV5
serotypes (6, 7). N-linked galactose is used for the transduction of
the rAAV9 serotype (8). Glycans expressed on the cell surface
dictate the tissue and cellular tropism observed with the various
AAV capsids. In addition to attachment to these glycans, AAV
serotypes interact with cell receptors, including human growth
factor receptor, integrins, and laminin receptors (9–11).
rAAV has shown promise for retinal gene transfer (12–16). In
addition to the influence of the capsid discussed above, the route
of administration to the retina determines the transgene expres-
sion profile and efficacy. Subretinal (SR) delivery deposits the vec-
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tor between the outer nuclear layer (ONL) and the retinal pigment
epithelium (RPE), which causes detachment of these two layers to
accommodate the injected solution. Many AAV serotypes display
transduction in the ONL and RPE layers, with some serotypes
showing restricted tropism (16). Of the natural serotypes, rAAV8
is one of the best for SR delivery based on its rapid transgene
expression and transduction of all retinal layers (17, 18). In addi-
tion to SR delivery, vectors can be administered to the vitreous.
Intravitreal (IVit) delivery of rAAV vectors has become the pre-
ferred route to the SR space for several reasons, including (i) tech-
nical ease of injection, (ii) the potential to deliver vector to a
greater area of the retina, and (iii) less damage to the retina. For
clinical applications, IVit delivery can be performed as an outpa-
tient procedure and would not exclude patients with severe retinal
degeneration. However, few serotypes exhibit efficient transduc-
tion by this route (19). rAAV2 is one of the few serotypes tested in
multiple animal models, typically resulting in the transduction of
retinal ganglion cells (RGC) (19–22). In rodent models, transduc-
tion with this serotype has been seen in occasional Müller glia,
amacrine, and horizontal cells. In addition, rAAV6 expression in
the RGC and inner nuclear layer (INL) has been seen in rodent
models (23–25). Understanding viral trafficking and barriers to
efficient IVit transduction provides opportunities to rationally de-
sign capsids to overcome current limitations.
At the vitreoretinal junction, the inner limiting membrane
(ILM) has been implicated as the barrier responsible for the inef-
ficiency of most rAAV vectors in transducing the retina. Despite
the limited transduction, several AAV serotypes are capable of
accumulating at the vitreoretinal junction following delivery (19,
20). Injections of fluorescently labeled capsids (rAAV1, -2, -5, -8,
and -9) into the vitreous of adult rodents showed that rAAV2,
rAAV8, and rAAV9 accumulated at the ILM, but only rAAV2
resulted in transduction (19). With a degenerated ILM, all of these
AAV serotypes were capable of transducing the retina (20). The
ILM is composed of the extracellular matrix of the Müller glial
endfeet, which display an array of glycans similar to those of other
basement membranes (26, 27) and prevent access to cells needed
for AAV transduction. The binding of rAAV2, rAAV8, and rAAV9
is likely explained by laminin interaction; however, accumulation
of laminin appears insufficient for transduction of rAAV8 and
rAAV9. HSPG binding of rAAV2 could explain the selective trans-
duction, but enzymatic digestion of HSPG has been shown to
increase the transduction and penetration of rAAV2 in the retina
(28). Because rAAV2 has shown HSPG-independent transduction
in other tissue (29, 30), it is possible that rAAV2 does not need
HSPG binding for retinal transduction and that HSPG may pre-
vent the spread of rAAV2 particles to the outer retina. Thus,
rAAV2 capsid interactions with HSPG at the ILM compose the
rate-limiting step for efficient IVit transduction of the retina. Un-
derstanding these interactions will help guide the rational design
of vectors for more efficient IVit transduction.
To study rAAV interactions at the ILM, we used a collection of
capsids with altered glycan usage. We used a self-complementary
chicken -actin, shortened form (CBh)–green fluorescent protein
(GFP) cassette for optimized transgene performance. The CBh pro-
moter is a shortened form of the chicken-actin (CBA) promoter
with the addition of cytomegalovirus (CMV) enhancer elements.
The CBh promoter has shown exceptional activity in other neu-
ronal tissue compared to CMV or CBA promoter activity (31)
without potential silencing issues, and its small size is beneficial
for maximizing the limited transgene capacity of rAAV. The self-
complementary form of the transgene facilitates faster expression
that is more robust than that of the classic single-stranded form
(17, 32, 33). This self-complementary form can also facilitate pro-
duction of transgene product in cells that do not provide second-
strand synthesis. In addition to optimizing GFP production, we
used fluorescence in situ hybridization (FISH) to track the vector
following IVit delivery to obtain an accurate picture of rAAV traf-
ficking. Genetic capsid mutations were used to understand the
role of heparan sulfate (HS) binding in rAAV transduction of the
mouse retina without modifying the ILM structure. We used
known capsid mutations in the HS-binding footprint of rAAV2 to
carry out this analysis. The motif on the rAAV2 capsid consists of
a basic patch of residues (R484, R487, K532, R585, and R588) at
the base of the 3-fold spike (30). Capsid mutants, like rAAV2i8,
replace residues 585Q and 588T to ablate HS binding and alter
tropism away from HS-rich liver tissue to become more systemic
when delivered intravenously (29). Using these capsid mutants,
we investigated the unilateral necessity for HS binding in retinal
transduction.
MATERIALS AND METHODS
Vector production andpurification. Self-complementary rAAV carrying
the GFP gene under the control of the ubiquitous CBh promoter (34) were
produced by the triple-transfection method using polyethylenimine (35).
Viruses were harvested as previously described (36). Lysate was clarified
by centrifugation at 6,200  g and purified by iodixanol gradient ultra-
centrifugation at 402,000 g for 1 h. Viruses were pulled from the 40% to
60% interface, purified by ion-exchange chromatography on a 1-ml Q
HyperD F column (Pall), and eluted with 200 mM NaCl, 25 mM Tris (pH
9.0). It was difficult to produce a significant yield of AAV8-E533K vector
with iodixanol. Therefore, AAV8 and AAV8-E533K were purified with
CsCl and then with sucrose to obtain pure vector. The viruses were dia-
lyzed against 350 mM NaCl, 5% sorbitol in 1 phosphate-buffered saline
(PBS) before being aliquoted and frozen at 80°C. The viral titer was
determined by quantitative PCR (qPCR) against wild-type inverted ter-
minal repeats (ITR) of DNase-resistant vector genomes relative to a virus
standard (data not shown). The viruses underwent electrophoresis on a
1% Bis-Tris gel (Novex) with silver staining (Life Technologies) to assess
purity (data not shown).
Animal injections. Adult C57BL/6 mice were used for this study. All
the animals were housed under a 12-h/12-h light/dark cycle in the Uni-
versity of North Carolina Division of Laboratory Animal Medicine facil-
ities and were handled in accordance within the guidelines of the Institu-
tional Animal Care and Use Committee at the University of North
Carolina. Prior to vector delivery, the animals were anesthetized with
ketamine (75 mg/kg of body weight), xylazine (10 mg/kg), or aceproma-
zine (1.5 mg/kg), and dilated with 1% tropicamide and 2.5% phenyleph-
rine. Proparacaine-HCl was applied to the eyes as a local anesthetic. In-
traocular needles were constructed using a 32G canula connected to a
Hamilton syringe via tubing filled with water. An air bubble separated the
water from the viral suspension. Freshly thawed viruses were diluted to
working stock and incubated in the intraocular needle at room tempera-
ture for 10 min prior to injection. The needles were evacuated and loaded
with fresh suspension. The viral suspension was mixed with fluorescein
sodium salt (Sigma) to confirm successful injection as previously de-
scribed (37). All injections were carried out by the same surgeon. For IVit
injections, a pilot hole was made with the tip of a beveled 30G needle in the
superior portion of the eye approximately 0.5 mm posterior to the limbus.
The intraocular needle was inserted through this hole into the vitreous
under direct observation through a microscope. A volume of 1 l was
delivered at a constant rate over 30 s using a syringe pump. The needle was
held in place for 20 s to allow intraocular pressure equilibration before
removal. For SR injection, the intraocular needle was inserted tangential
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to the eye. Delivery of fluid was immediate and was characterized for
success by optical coherence tomography (OCT) and fundoscopy of flu-
orescein distribution using the Micron IV (Phoenix Research Laborato-
ries). Genteal (Novartis) was applied to the eyes to prevent corneal drying,
and the mice were allowed to recover on heating pads.
In vivo imaging. Fundus images and OCT were carried out by dilating
and sedating the animals as described above. All fluorescent images were
taken under the same settings and with similar retinal positions using the
Micron IV. The green channel of the fluorescent fundus image was iso-
lated, converted to grayscale, and quantified by integrated density mea-
surements using ImageJ (National Institutes of Health).
Enucleation and histology. The animals were sedated and perfused
with PBS containing 1 unit heparin per ml, followed by 4% paraformal-
dehyde (PFA) in PBS. The eyes were enucleated, and a puncture was made
anterior to the limbus using an 18G needle before incubation in 4% PFA
for 10 min. The anterior segment, musculature, and lens were removed,
and eyecups were placed in 10% sucrose at 4°C overnight, followed by
20% and 30% sucrose incubations. The eyecups were embedded in OCT
cutting medium (Sakura), frozen at 20°C, and stored at 80°C. Ten-
micrometer transverse sections were collected on precleaned Superfrost
Plus slides (Fisher) and stored at80°C until further processing.
Immunohistochemistry (IHC) and analysis. Sections were washed in
Tris-buffered saline (TBS) containing 0.3% Tween 20 (TBS-T) and incu-
bated in blocking buffer (10% normal goat serum [NGS], 0.1% Triton
X-100 in PBS) for 1 h in a humid chamber. The slides were incubated in
antibody solution (3% NGS, 0.1% Triton X-100 in PBS) with primary
antibodies in a humid chamber overnight at room temperature. The pri-
mary antibodies used were rabbit anti-GFP (1:500; Millipore), mouse
anti-glutamine synthetase (1:100; Abcam), mouse anti-heparan sulfate
10E4 epitope (1:70; Amsbio), mouse anti-rhodopsin (1:100; Rockland),
mouse anti-protein kinase C (PKC) alpha (H-7; 1:250; Santa Cruz), and
fluorescein Erythrina cristagalli lectin (1:100; Vector Laboratories). After
three washes with TBS-T, secondary fluorescent antibodies were applied
in antibody solution for 2 h in a humid chamber. The secondary antibod-
ies were Alexa Fluor 488 goat anti-rabbit (1:1,000; Molecular Probes),
Alexa Fluor 568 goat anti-mouse (1:1,000; Molecular Probes), and Alexa
Fluor 568 rabbit anti-goat (1:1,000; Molecular Probes). The slides were
mounted in Prolong Gold antifade reagent with 4=,6-diamidino-2-phe-
nylindole (DAPI) (Molecular Probes) according to the manufacturer’s
protocol. Images were taken on a LeicaSP2 AOBS upright laser scanning
confocal microscope or an Olympus IX83 fluorescence microscope.
Soluble HS analog assays. For in vitro studies, HEK293 cells were
plated in a 24-well dish at a density of 105 cells per well and allowed to
adhere overnight at 37°C, 5% CO2. Viruses were preincubated with solu-
ble heparin at the specified concentrations for 1 h prior to addition to cells
at a concentration of 10,000 viral genomes (vg) per cell. The cells were
harvested 48 h later and quantified by flow cytometry.
Fluorescence in situhybridization.The GFP gene was cloned into the
pSPT18 vector (Roche RNA in vitro transcription kit) at the HindIII and
EcoRI sites and sequenced for confirmation. Plasmids were linearized
with these restriction enzymes and purified by phenol-chloroform extrac-
tion/ethanol precipitation and resuspended in water. The linearized plas-
mids were quantified by spectrophotometry and verified by DNA se-
quencing before in vitro transcription of antisense and sense riboprobes
was carried out as described by the manufacturer (Roche). Aliquots of
riboprobes were frozen in water and were quantified as described by the
manufacturer and analyzed by gel electrophoresis and SYBR Gold staining
(Invitrogen). Riboprobe functionality was assayed for sensitivity and se-
lectivity by dot blotting of virus controls to a positively charged nitrocel-
lulose membrane (Roche). The sense and antisense probes were equally
able to detect the viral GFP transgene (data not shown).
Frozen slides were heated to 55°C for 10 min and pretreated as previ-
ously described (38). The slides were then incubated in hybridization
buffer (50% formamide, 10 mM Tris [pH 7.6], 200 g/ml Saccharomyces
cerevisiae tRNA, 1 Denhardt’s solution, 10% dextran sulfate, 600 mM
NaCl, 0.25% SDS, 1 mM EDTA [pH 8]) without probe at a hybridization
temperature of 65°C for 2 to 4 h. The slides were transferred to prehybrid-
ization buffer containing 50 ng/ml of sense riboprobe to specifically detect
DNA and not mRNA transcripts. The slides were heated to 80°C for 20
min, snap chilled on ice, and incubated overnight at 65°C. The slides were
washed in 50% formamide-2 SSC (1 SSC is 0.15 M NaCl plus 0.015 M
sodium citrate) at 65°C for 30 min and in 2 SSC at 55°C for 20 min, with
two washes with 0.2 SSC at 55°C for 20 min each time. The slides were
washed in 1 washing buffer (Roche), followed by incubation with 10%
sheep serum in 1 blocking buffer for 1 h in a humid chamber. Sheep
anti-digoxigenin (DIG)-allophycocyanin (AP) antibody (1:1,000; Roche)
was applied and incubated for 2 to 3 h in a humid chamber. The slides
were washed three times in washing buffer with gentle agitation for 10 min
each time, followed by two incubations in detection buffer (100 mM Tris,
100 mM NaCl, 10 mM MgCl2 [pH 8.0]) for 10 min each time. HNPP/Fast
Red detection substrate was prepared and applied as directed by the
manufacturer (Roche) for two or three applications. Following the
detection reaction, the slides were rinsed in distilled water and cover-
slipped using Prolong Gold antifade reagent with DAPI. Images were
taken on a LeicaSP2 AOBS upright laser scanning confocal microscope
or an Olympus IX83 fluorescence microscope.
Ex vivo human retinal-binding assay. Human whole globes were
procured immediately after death and placed in a moist chamber on ice
for 4 days. The anterior chamber, iris, and lens were removed, and the
globe was quartered, with some vitreous remaining attached to the retina.
Ten microliters of vector was applied to the vitreous at a titer of 2 109
vg/l and allowed to bind to the retina for 2 h at 4°C. The quartered retinas
were kept out of medium to prevent the dispersion of the vector solution.
Following the incubation, PBS was washed over the tissue, collected, and
stored at80°C. Vitreous, retina, choroid, and sclera were collected sep-
arately and stored at 80°C. The tissue samples were digested and puri-
fied using the DNeasy blood and tissue kit (Qiagen). Virus in the collected
samples was quantified by qPCR using primers against the GFP and hu-
man glyceraldehyde-3-phosphate dehydrogenase (hGAPDH) housekeep-
ing genes.
RESULTS
HS binding on rAAV2 is not required for SR transduction. A
variety of AAV serotypes, both HS binding and non-HS binding,
work effectively in retinal transduction when delivered subreti-
nally, suggesting that HS binding is not needed for outer retinal
transduction. To determine if rAAV2 requires HS binding in the
transduction of the outer retina, HS binding was ablated using the
rAAV2i8 capsid and subretinally delivered. Transductions be-
tween rAAV2 and rAAV2i8 were similar by fundoscopy. The
strongest signal of GFP fluorescence could be seen within the de-
tached area (Fig. 1a, dashed lines), but additional expression could
be seen outside the bleb area for both vectors (Fig. 1a). The trans-
duction that was outside the detachment appeared to be mostly
RPE. Within the detachment, transduction of multiple layers was
observed, as evidenced by the fluorescent RGC axons leading to
the optic head from the site of injection (Fig. 1a, arrowhead).
IHC was used to evaluate the cell tropism between the two
vectors. The RPE and ONL were the major cell layers transduced
by both vectors (Fig. 1b). Areas where high RPE transduction but
low ONL transduction occurred could be seen, indicating that
RPE may be the predominant cell type to be transduced. Trans-
duction of the ONL occurred predominantly in rods for both
rAAV2 and rAAV2i8 capsids (see Fig. S1a in the supplemental
material). Similar to the transduction of rAAV2, cells transduced
by rAAV2i8 in the INL were identified as rod bipolar cells and
Müller glia (see Fig. S1b and c, arrowhead, in the supplemental
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material). These results confirm that the rAAV2i8 capsid is infec-
tious in retinal tissue by SR delivery.
HS binding of rAAV2 is required for intravitreal transduc-
tion. Next, we were interested in assessing whether HS binding is
necessary for IVit transduction of rAAV2. Both rAAV2 and
rAAV2i8 capsids were delivered intravitreally to adult mice at a
titer of 108 vg. rAAV2-injected eyes were fluorescent at the first
imaging time point of 2 weeks, whereas rAAV2i8 showed no ex-
pression (data not shown). The eyes were evaluated for up to 12
weeks for the possibility of slower expression kinetics. During that
time, rAAV2 fluorescence continued to increase, but no fluores-
cence was detected with rAAV2i8. By 12 weeks, rAAV2 capsid led
to a diffuse pattern of fluorescence over the neural retina, as seen
by fundus imaging (Fig. 2a). The rAAV2i8 capsid did not yield
observable GFP fluorescence by fundoscopy, which resulted in a
300-fold reduction in GFP fluorescence (Fig. 2a). We tried a
higher titer of 2  109 vg for both rAAV2 and its HS-binding
mutant to maximize the chance to observe expression. Of course,
the expression was much greater with higher titers of rAAV2 (see
Fig. S2a in the supplemental material) than what was observed
with the lower-titer-injected eyes (Fig. 2a), but the pattern of
transduction remained unchanged. We confirmed that the vitre-
ous did not specifically inhibit the transduction of the HS-ablated
rAAV2i8 capsid. To do this, virus was mixed with vitreous and
delivered subretinally. Both rAAV2 and rAAV2i8 shared intense
expression throughout most of the retina observed on fundoscopy
(see Fig. S3 in the supplemental material).
Eyes injected intravitreally with rAAV were further evaluated
by IHC. rAAV2 transduction was mainly detected in the RGC and
INL, and in some sections, transduction of photoreceptors could
be observed (Fig. 2b, arrows). The histology of HS-ablated rAAV2
capsids revealed a dramatic lack of transduction, except for a few
GFP-positive rods (Fig. 2b, arrows). Several mechanisms could be
responsible for this phenotype. The lack of RGC and INL trans-
duction with rAAV2i8 could be related to changes in either the
tropism or te distribution of the capsid. We chose to further ana-
lyze the tissue using FISH to determine the distribution of trans-
genes following IVit delivery. This is a better alternative to IHC
using antibodies against the capsid, since many of the capsid sub-
units would have dissociated to release the transgene. Similar to
IHC expression, FISH signal for rAAV2-delivered transgenes was
detected mainly in the RGC and INL (Fig. 2c). rAAV2i8-injected
eyes showed transgenes were present in the ONL, but no signal
was detected in either the RGC or the INL. These transgenes most
likely represent episomes that are stable following entry into the
retina by IVit delivery. It could be that the few transgenes in the
ONL represent a subpopulation of retinal cells that form stable
episomes, yet HS-deficient rAAV2 distributed similarly to rAAV2.
Equally possible was the hypothesis that HS-ablated rAAV2 al-
tered the distribution pattern within the retina.
HS binding is necessary for the vitreal accumulation of
rAAV2 at the ILM in mice. To obtain a better understanding of
the trafficking differences between the capsids following IVit de-
livery, eyes were enucleated soon after injection for FISH analysis.
Because we had established that exposure of charged residues on
the capsid surface plays an important role in transduction, we
used FISH as an alternative to modifying the capsid with fluores-
cent particles for trafficking experiments. Previous reports had
shown that AAV particles accumulate at the ILM 24 h postinjec-
tion (19), which was confirmed using our FISH protocol, indicat-
ing that we could detect transgenes carried in capsids that were still
intact (data not shown). The time point was extended to 3 days
postinjection to allow sufficient time for capsid accumulation at
the ILM and to observe trafficking differences between the rAAV2
capsid and its HS-binding mutants. We used a range of doses to
capture any concentration effect in accumulation and shortened















FIG 1 GFP fluorescence following subretinal delivery of rAAV2 and HS-de-
ficient rAAV2i8 vector 8 weeks postinjection. (a) Representative fundus im-
ages and fluorescence of eyes treated with rAAV2i8 capsid and rAAV2 capsid.
The dashed lines indicate detached areas of injection. Transduction was great-
est in the bleb, but transduction of the RPE can be seen outside the initial bleb
site. Transduction of ganglion cells can be observed by the GFP fluores-
cence of axons leading from the injection site to the optic disc in rAAV2-
injected eyes (arrowhead). (b) Histology of eyes indicated similar trans-
duction of RPE and ONL between rAAV2 and its HS-deficient rAAV2i8
vector. Expression of the INL and RGC by rAAV2 can be seen, but it is
minimal for rAAV2i8. Scale bar  20 m.
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namic range. PBS-injected eyes served as the negative control,
which had minimal background labeling (Fig. 3a). With the short-
ened detection time, a dose of 1 108 vg had only weak signal in
retinas for both rAAV2 and HS-deficient rAAV2-R585E capsids.
At a dose of 5 108 vg, transgenes delivered by rAAV2 showed an
accumulation at the ILM (Fig. 3a, arrows), as well as being present
in the ONL (Fig. 3a, arrowheads). Without HS binding, rAAV2-
R585E had only minimal signal in the ONL. At the highest dose
tested (2 109 vg), rAAV2 resulted in even greater signal intensity
at the ILM (Fig. 3a, arrows), showing increased accumulation of
the vector. Additional aggregation of transgenes was seen in the
ONL (Fig. 3a, arrowheads). At the same dose, a few rAAV2-
R585E-delivered transgenes were detected in the ONL of the ret-
ina (Fig. 3a, arrowheads) but did not result in any accumulation at
the ILM (Fig. 3a). Taken together, these results indicate (i) that HS
binding on rAAV2 helps to accumulate vectors at the ILM, (ii) that
this accumulation increases the number of transgenes residing in
the retina, and (iii) that capsids can penetrate the retina from the
vitreous without binding to HS, but to a far lesser extent (Fig. 3b).
Once capsids pass through the ILM barrier, they seem capable of
trafficking rapidly to distal layers of the outer retina. This high-
lights the fact that rAAV’s rate-limiting step for efficient intravit-
real transduction of the retina lies in the interaction between the
capsid and the ILM.
HS binding is necessary for the vitreal accumulation of
rAAV2 on human retinas. The abundant HSPG staining at the
ILM in many animal models, including humans (see Fig. S4 in the
supplemental material), suggests this mechanism may translate
across species for human clinical applications. To evaluate this
hypothesis, a viral binding assay was done on human retinas ex
vivo by quartering the eye and leaving a small amount of vitreous
attached to the retina to maintain the ILM structure. Vectors were
applied to the vitreous, followed by harvesting of the various ret-
inal layers. Transgenes carried by rAAV2 were bound to the retina,
unlike those of the rAAV2i8 capsid (Fig. 4). The HS-deficient
rAAV2i8 had relatively low vector binding in any of the collected
tissues but did show a significant increase in binding to the cho-
roid and sclera compared to rAAV2. Together with the mouse
data, these results corroborate a mechanism in which HS binding
promotes the accumulation of AAV vector out of the vitreous and
onto the ILM for greater retinal penetration and transduction.
HS binding increases the IVit transduction of other rAAV
serotypes. IVit transduction of other serotypes may benefit from
the addition of the HS-binding motif and add to the diversity of
vectors that could be used. The rAAV1 and rAAV6 serotypes differ
by only 6 amino acids, with a single residue responsible for the
difference in HSPG binding (39, 40). To evaluate the influence of
HS binding between rAAV1 and rAAV6 retinal transduction for





















FIG 2 GFP fluorescence following intravitreal delivery of rAAV2 vector and
its HS-binding-deficient variants 12 weeks postinjection. (a) (Top) Represen-
tative fundus images and fluorescence of eyes treated with rAAV2 capsid or
rAAV2i8 capsid. rAAV2 capsid produced a large area of fluorescence, while the
heparan sulfate-binding-deficient capsid showed no observable fluorescence.
(Bottom) Quantification of fundus images showing a 300-fold decrease in
expression between rAAV2 and rAAV2i8. The error bars indicate standard
errors of the mean (SEM), and significance was detected by a nonparametric t
test (**, P  0.01). (b) IHC of rAAV2-injected retinas showing fluorescence
mainly in the RGC, with fewer GFP-positive somas in the INL. rAAV2i8
showed minimal transduction of the retina. Rare transduction of photorecep-
tors could be observed (arrows). (c) FISH substrate was applied three times to
maximize sensitivity and detected the locations of transgenes within the retina.
Transgenes were detected mainly in the RGC and INL for rAAV2 capsid. A few
GFP transgenes in the retina (arrowheads) were in the ONL for rAAV2i8. Scale
bars 20 m.
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intravitreally in mice. Although rAAV1 and the HS-binding
rAAV1-E531K had similar patterns of expression, rAAV1-E531K
had 3-fold-greater GFP fluorescence than rAAV1 (Fig. 5a). The
removal of HS binding in rAAV6 using the rAAV6-K531E capsid
led to a reduction in retinal fluorescence by fundoscopy, as hy-
pothesized (see Fig. S5a in the supplemental material). Both
rAAV1 and rAAV6 capsids displayed a punctate expression pat-
tern that clustered around the retinal vessels and that has been
documented in other reports (23, 24). Because of the homology
between rAAV1 and rAAV6, only rAAV1 and rAAV1-E531K were
further evaluated for possible differences in cell tropism. IHC per-
formed on these retinas showed the transduction of mainly Müller
glia for both capsids by the colocalization of GFP and glutamine
synthetase (Fig. 5b, arrowheads). Additional cells of the INL ap-
peared to be transduced (Fig. 5b, arrows). In addition, both
rAAV1 and rAAV1-E531K showed transduction of a few RGC and
photoreceptors. The similar transduction patterns of rAAV1 and
rAAV1-E531K indicate that HS binding had not altered the tro-
pism of rAAV1. To confirm that the HS-binding mutation on
rAAV1 does not convey use of HSPG for transduction, soluble
heparin was mixed with capsids and applied to cells for an in vitro
competition assay. rAAV2 required HSPG for in vitro transduc-
tion (4) and showed a dose-dependent decrease in transduction
(see Fig. S6 in the supplemental material). Neither rAAV1 nor
rAAV1-E531K transduction was affected at any heparin dose, in-
dicating that the rAAV1-E531K capsid does not depend on HS
binding for transduction. On average, transduction with rAAV1-
E531K led to fewer GFP-positive cells than transduction with
rAAV1, indicating that the single-amino-acid change alone does
not provide an enhancement in transduction.
In the same article outlining the amino acid involved in
rAAV1/rAAV6 transduction, a single-amino-acid mutant was
identified on rAAV8, which provided HS-binding capability (39).





























Time following intravitreal delivery
Hours Days Weeks
non-HS binding capsid HS binding capsid
a
b
FIG 3 FISH of intravitreally injected eyes 3 days postinjection. (a) PBS-in-
jected eyes served as a negative control for FISH detection and had low back-
ground. The arrowheads indicate FISH signal. Weak signal was detected in the
retinas of eyes injected with 1 108 vg for rAAV2 and rAAV2-R585E. rAAV2
at a dose of 5  108vg showed accumulation of the transgene at the ILM
(arrows), with some detectable transgenes in the outer retina (arrowheads). A
dose of 5 108 vg led to weak signal for rAAV2-R585E. A high dose of 2 109
vg revealed greater accumulation of rAAV2 capsids at the ILM (arrows) and
within the retina (arrowheads). At the same dose, rAAV2-R585E showed a
greater presence in the retina within the ONL (arrowheads). (b) Schematic of
the retina depicting the trafficking of rAAV following IVit delivery. Scale bar
20 m.
FIG 4 qPCR analysis of viral binding to human retinas ex vivo. The rAAV2
vector showed the greatest presence at the retina, with few transgenes found
elsewhere. The numbers of transgenes delivered by rAAV2i8 were low in all
collected tissues but showed a significant increase compared to rAAV2-deliv-
ered transgenes in both the choroid and sclera. The error bars indicate stan-
dard deviations. *, P 0.05.
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and injected intravitreally. At 8 weeks postadministration, fundus
images revealed low GFP fluorescence for rAAV8 (see Fig. S7 in
the supplemental material). Injection of eyes with rAAV8-E533K
resulted in hazy fluorescence over the retina that, when quantified,
was greater than that of the non-HS-binding parent serotype. We
used FISH analysis to observe trafficking differences soon after
injection and found again that HS binding promoted the accumu-
lation of vector at the ILM and within the retina (see Fig. S8 in the
supplemental material). These results suggest that HS binding
alone is sufficient to enhance the transduction of intravitreally
delivered AAV capsids by increasing the amount of vector that
accumulates on the retina.
Other capsidmotifs determine tropism over theHS-binding
motif. The addition of the HS-binding motif helped to increase
vector accumulation on the retina but did not alter the transduc-
tion pattern of rAAV1, indicating that native capsid motifs deter-
mine tropism. We were interested in determining if capsid motifs
from other AAV serotypes could influence the transduction of
rAAV2. A motif of rAAV1 was graphed onto the rAAV2 capsid using
the rAAV2.5 capsid (41), which was delivered by IVit for analysis.
While distinct from either parental serotype, the rAAV2.5 capsid
revealed an expression pattern surrounding the retinal vessels
(Fig. 6a). IHC of these eyes did not reveal any major tropism
differences compared to rAAV2, in that RGC, Müller glia, and
other cells of the INL were transduced by the chimeric capsid. A
more recent paper has shown the amino acid at position 265 on
the rAAV2.5 capsid to be solely responsible (42). Therefore, we
tested an rAAV2-265D mutant capsid intravitreally, which re-
vealed expression similar to that of the rAAV2.5 parent (see Fig. S9
in the supplemental material).
We chose to test an additional chimeric rAAV2 capsid that had
dual HS and galactose binding capabilities. The chimeric
rAAV2G9 was used and was found to have a punctate expression
across the retina (Fig. 6b). The IHC showed a specific tropism to
Müller glia. The galactose motif was structured from the rAAV9
capsid. By fundoscopy, both rAAV9 and HS-ablated rAAV2i8G9
capsids showed no expression following IVit delivery (see Fig.
S10a in the supplemental material), indicating that galactose
binding alone was insufficient to lead to transduction within the
retina.
A double-chimeric capsid, rAAV2.5G9, was used to deter-
mine which of the capsid motifs, rAAV1 or rAAV9, was dom-
inant. The intravitreal delivery of rAAV2.5G9 led to expression
similar to that of the rAAV2.5 parent when imaged by fundos-
copy (Fig. 6c). The fluorescence around the retinal vessels was
very evident, with punctate expression found around the ves-
sels. IHC of the rAAV2.5G9-injected eyes revealed a largely
Müller glia-dominant tropism (Fig. 6c). Quantification of a
comparison of all the fundoscopy expression showed rAAV2.5
and rAAV2.5G9 to have the highest transduction, with non-
HS-binding capsids showing the lowest transduction (Fig. 6d).
We used a lectin antibody to identify the presence of galactose
throughout the retina; however, the majority of the staining
occurred around the ONL without a clear connection to Müller
glia (see Fig. S10b in the supplemental material). Therefore, the
addition of either the rAAV1 or rAAV9 motif appeared to have
equal abilities to control tropism, which is dominant over the





























FIG 5 GFP fluorescence following intravitreal delivery of HS-binding variants
of rAAV1 8 weeks postinjection. (a) (Top) Representative fundus images and
fluorescence of eyes treated with rAAV1 capsid or rAAV1-E531K capsid. Both
capsids produced punctate staining that clustered around the retinal vessels.
(Bottom) Quantification of fundus images showing a 3-fold increase with
rAAV1-E531K capsid compared to rAAV1 capsid. The error bars indicate
SEM, and significance was determined by a nonparametric t test (*, P 0.05).
(b) GFP IHC of retinal sections 8 weeks after injection of rAAV1 and rAAV1-
E531K capsids. The images show the colocalization (arrowheads) of GFP with
Müller glia markers for rAAV1 and rAAV1-E531K. The individual channels
show GFP and glutamine synthetase expression in the retina. Additional stain-
ing of non-Müller glia (arrows) can be seen. Confocal z-stack images were
compressed and are displayed as maximum projections. Scale bar 50 m.
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DISCUSSION
With the experiments conducted in this study, we gained a greater
understanding of the early trafficking of rAAV following intravit-
real delivery. As virus is injected into the vitreous, it radiates out-
ward from the needle and travels through the vitreous humor.
This stochastic dispersion of vector in the vitreous results in a
dilution of the vector concentration. Once at the junction, the
capsid interacts with the glycans present on the ILM to effectively
concentrate the virus outside the vitreous. This interaction occurs
on the order of days following delivery. After concentration of the
virus, the vector begins to penetrate the retinal layers, where it
infects various retinal cells. In the weeks after delivery, transgene
expression is detectable and remains so for months. Not all AAV
serotypes aggregate sufficiently to promote penetration into the
retina and to lead to transgene expression. This can be circum-
vented through the application of HS-binding motifs on the cap-
sid, thereby allowing the capsid to interact with the ILM without
causing a change in tropism.
The interaction of rAAV capsids with the ILM is the rate-lim-
iting step for retinal trafficking (19, 20). Therefore, interaction
with the membrane should be increased to maximize the number
of capsids entering the retina. Pores present in the ILM may ex-
plain why few HS-binding-deficient capsids were able to pass
through the ILM and traffic rapidly to the outer retina (Fig. 3; see
Fig. S8 in the supplemental material). Similar numbers of rAAV2
capsids were found rapidly in the outer retina, supporting the idea
of a non-glycan-mediated entry, as through a pore. These deeply
penetrating vectors may represent the few capsids whose trajecto-
ries were aligned to allow them to quickly pass through the pores
and through the retinal interior. However, the majority of vectors
must interact with the ILM before they can penetrate into the
retina. If capsids cannot interact with the ILM, they remain di-
luted in the vitreous, unable to transduce the retina. Even if a
higher concentration of vector is used, the lack of interaction with
the ILM prevents capsids from aggregating onto the retina surface
and transducing the retina. We were able to increase the amount
of vector in the retina by adding an HS-binding motif to the non-
HS-binding capsids. Currently, the methods for getting vector
into the retina using high-titer virus are to either digest the ILM or
perform a sub-ILM injection (19–21, 43). It is easy to see how
development of better capsids that are capable of transducing
without these aids would be of interest to researchers and clini-
cians alike.
The ILM structure is found across multiple species (see Fig. S4
in the supplemental material) and could serve to attract and con-
centrate rAAV capsids outside the vitreous, not just for mice, but





























FIG 6 Chimeric capsids suggest tropism is influenced by motifs other than HS
binding. (a) Elements of rAAV1 were applied to rAAV2 using the chimeric
rAAV2.5 capsid and imaged for intravitreal delivery. The histology of rAAV2.5
showed transduction of Müller glia, as seen with glutamine synthetase colabel-
ing. In addition, RGC expression is present. (b) Elements of rAAV9 were
applied to rAAV2 using the chimeric rAAV2G9. Histology of rAAV2G9
showed mostly transduction of Müller glia, as seen with glutamine synthetase
colabeling. (c) Transduction of the double-chimera rAAV2.5G9 capsid
showed a transduction profile similar to that of the rAAV2.5 parent capsid, as
seen by fundus imaging, and showed Müller glial transduction by IHC. (d)
Quantification of the fundus fluorescence for the collection of capsids. The
error bars represent SEM. Scale bars 50 m.
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tion on the retina with only the HS-binding rAAV2 using human
ex vivo retinas (Fig. 4). The kinetics of vector dispersion through
the vitreous humor are likely to be slower due to the volume,
which also means longer times until interaction with the ILM and
penetration into the retina. Studies in nonhuman primates re-
vealed that vector accumulated at the ILM 1 month after intravit-
real injection but remained abundant in the vitreous (data not
shown). Although these kinetic studies must be worked out fur-
ther for primate intravitreal delivery, the mechanism by which
HS-binding motifs positively influence vector accumulation on
the retina will make vectors more effective. It is important to re-
member that the transduction observed in a mouse model may
not be relevant to other models. While the mouse has become a
standard model for retinal gene transfer, certain size and anatom-
ical differences exist between them and larger-animal models. In
addition, the thickness differences of the ILM between mice and
primates may lead to selection of capsids that are not as efficient
across species. However, through the addition of the HS-binding
motif, we showed that our mechanism of vector accumulation is
conserved in both mouse and primate retinas.
The interaction between the AAV capsid and HS is mediated by
a static charge. The negative charge of the sulfate groups on the
heparan chain, which are found on the proteoglycan core of
HSPG, serves to attract the basic patch of residues on the rAAV2
capsid. Through this sulfate interaction, the heparin chain falls
along the inner surface of the 3-fold protrusion of the capsid sur-
face. We used capsid mutants to change this charge interaction to
no longer attract the sulfate group and to obstruct the heparan
chain interaction with the capsid. It could be argued that this
charge interaction is the most important interaction between
rAAV and the ILM; therefore, the capsid is really drawn to any
highly charged molecule. We used dextran sulfate to act as a sur-
rogate for heparan sulfate. We mixed rAAV2 capsids with dextran
sulfate or heparan sulfate (heparin) or unsulfated heparan sulfate
(heparosan) before IVit delivery. We found that heparin and
heparosan dramatically decreased transduction of rAAV2, while
dextran sulfate resulted in no change (data not shown). These data
indicate that rAAV2 specifically interacts with HSPG, not through
electrostatic charge alone. Therefore, random changes to make the
capsid more charged may have little influence.
Indeed, HS binding led to greater presence of transgenes in the
retina than the parent capsid when assessed by FISH soon after
injection (Fig. 3). Transgenes of non-HS-binding rAAV1 and
rAAV8 could still be detected in the retina, but to a lesser extent
(see Fig. S8 in the supplemental material). The lack of expression
with HS-binding rAAV3 when injected intravitreally (data not
shown) was expected, because the serotype is inefficient in the
transduction of most cell types (44) and may encounter additional
barriers to efficient transduction of cells. rAAV6 is a serotype of
interest for retinal transduction and has been modified to increase
the specific transduction of Müller glia using the ShH10 capsid
(45). Without HS binding, the ShH10 vector may show much
weaker fluorescence. Based on our data, we suggest that any capsid
that has an HS-binding motif would be capable of accumulating at
the ILM. The recent study published by Boye et al. used HSPG-
binding rAAV5 and rAAV8 but was unsuccessful in enhancing
their GFP fluorescence, indicating this HS-binding enhancement
is not universal to all capsids (46). We believe this to be related to
their shortened CBA promoter and that use of a different pro-
moter may reveal expression. We showed that HSPG binding on
rAAV8-CBh-GFP is capable of enhancing accumulation and ex-
pression. As predicted by our model and validated by FISH, this
was due to the HSPG binding-mediated interaction with the ILM.
We predict that rAAV5 capsid should have enhanced transduction
with the HSPG-binding mutation. In addition, other laboratories
have tested rAAV5 and rAAV8 using a CAG promoter and have
shown expression (47). This serves as a reason to reevaluate all
rAAV capsid transduction following intravitreal delivery by FISH.
Using GFP expression as the only way to analyze where capsids
have trafficked in the retina provides an incomplete picture of how
rAAV traffics in the retina following IVit delivery. FISH analysis
provides a simple way to detect the locations of viral transgenes as
a surrogate for the locations of capsids. This provides a better
alternative to modifying the capsid surface with fluorescent Cy3
dye, which binds to the Lys residues on the capsid. Modifying the
rAAV1 capsid to have more Lys residues (rAAV1-E531K), which
then bind to HSPG, increases transduction, so it could be argued
that the Cy3 dye could have masked the expression of serotypes in
earlier studies (19, 20).
Increasing the virus concentration could increase vector inter-
action with ILM but is more likely to evoke an immune response,
as the vitreal space is not immune privileged like the subretinal
space (48). Therefore, it is optimal to use lower concentrations of
vector to avoid this response. This is why we chose to work with a
low concentration of vector to maximize expression rather than
using high titers of vector. Other laboratories sought to maximize
expression in other ways. In a recent study, selection of a peptide
incorporated into the rAAV2 capsid showed ONL transduction
from the vitreous in both mice and nonhuman primates (49).
While this peptide is located near the HS-binding footprint, the
capsid shows a dependency on HSPG for transduction and may
still exploit the same HS-mediated accumulation mechanism out-
lined here. We tested this hypothesis by using the amino acid
mutants discussed here, along with the peptide, delivered intrav-
itreally to adult mice. As predicted by our model, GFP expression
was detected only when the Arg residues involved in the HS-bind-
ing motif were present (data not shown). We found that the pep-
tide insertion reduced rAAV2 transduction, suggesting that a re-
duction in HSPG binding is met with a reduction in IVit
transduction. A recent publication has reported that the mecha-
nism exploited by the peptide is intracellular (47). Other attempts
to enhance transduction used capsids modified to avoid protea-
somal degradation (50), thereby enhancing intracellular traffick-
ing to help increase the transgene expression of intravitreally de-
livered capsids. However, a recent publication suggests that these
vectors may not benefit from proteasome avoidance (46). These
capsid changes work downstream of ILM binding once the vector
has penetrated the retina. To take advantage of the retinal struc-
ture, binding to the ILM can be used to accumulate vectors at the
retina for transduction. This is likely why rAAV2 has been success-
ful at intravitreal retinal transduction.
Although HSPG is abundant at the ILM, other receptors can
play a role in the transduction of the retina from the vitreous. The
transduction by rAAV1 and rAAV6 suggests the presence of 2,3-
or 2,6-N-linked sialic acid at the ILM despite the lack of staining in
that region (data not shown). The pattern of transduction ob-
served by fundus imaging may indicate a distinct pattern of this
sialic acid in the retina that is not visible by histology but that
could be seen by flat-mount staining. It would be beneficial to
perform FISH on whole-mount retinas soon after injection to
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observe accumulation of vector. It may be that these serotypes
aggregate only at specific retinal structures or that vector aggre-
gates along the entire inner retinal surface but leads to transduc-
tion only in specific regions. By performing FISH on whole
mounts, we would gain a better understanding of the phenotype
observed with the chimeric rAAV2.5 and rAAV2G9 capsids. Other
forms of sialic acid known to interact with rAAV4 and rAAV5 may
not be expressed abundantly at the ILM or could be masked by
other glycans. This would explain the lack of transduction by these
serotypes when compared in a normal mouse retina. In addition
to sialic acid, laminin staining is abundant at the ILM and is re-
stricted to the blood vessels. Laminin receptor is known to interact
with the rAAV2, rAAV3, rAAV8, and rAAV9 serotypes (10). Al-
though these capsids can interact with laminin receptors at the
vitreoretinal junction, this interaction seems insufficient to pro-
mote efficient intravitreal retinal transduction. Again, a reevalua-
tion of all rAAV serotypes using FISH as the detection method
would provide a greater understanding of virus trafficking and
transduction in the retina.
The similar transduction profiles of SR-delivered rAAV2 and
rAAV2i8 indicate that rAAV2 does not require HS binding for
retinal transduction (Fig. 1). It may be that subretinal delivery
effectively concentrates the vector, thereby stoichiometrically
skewing capsids toward expression. In addition to transduction by
receptor-mediated endocytosis, SR delivery provides abundant
rAAV vectors to the phagocytic RPE and may explain why the RPE
appears to be the primary cell target of both rAAV2 and rAAV2i8.
Regardless of affinity for any particular cell type, rAAV2 and
rAAV2i8 vectors lead to transduction of RPE, rods, cones, rod
bipolar cells, and Müller glia (see Fig. S1 in the supplemental ma-
terial). The majority of these transduced cells are located within
the injection bleb, but transduction of the RPE can be seen far
outside the detached area. It would be of interest to see if the RGC
transduction of subretinally delivered rAAV2 is due to the HSPG
on the ILM pulling on the vector. FISH could be used to map the
trafficking of SR-delivered vector to better understand this phe-
nomenon.
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